SCHEMBL6927205

SCHEMBL6927205

CCN1CCN(c2cc(-c3nc(-c4ccc(F)c(F)c4)c[nH]3)ccn2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.40
PIK3C3 Q8NEB9 1/20 0.40
WNT1 P04628 1/20 0.39
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39
LRRK2 Q5S007 4/20 0.38
ZAP70 P43403 1/20 0.38
DRD2 P14416 5/20 0.38
HTR2A P28223 5/20 0.38
ITGB2 P05107 2/20 0.37
ICAM1 P05362 2/20 0.37
ITGAL P20701 2/20 0.37
TRPV3 Q8NET8 1/20 0.37
METAP2 P50579 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925663 0.91 PTPN11 (0.42) PIK3C3WNT1GSK3BDYRK1ALRRK2
SCHEMBL6925464 0.91 DRD2 (0.44) WNT1GSK3BDYRK1ALRRK2ZAP70
SCHEMBL6925150 0.90 WNT1 (0.42) KCNH2PIK3C3WNT1GSK3BDYRK1A
SCHEMBL6921690 0.88 SMG1 (0.41) PIK3C3WNT1GSK3BDYRK1ALRRK2
SCHEMBL6921703 0.88 LRRK2 (0.43) KCNH2PIK3C3LRRK2ITGB2ICAM1
SCHEMBL6924877 0.87 PIK3C3 (0.38) KCNH2PIK3C3LRRK2TRPV3CYP11B1
SCHEMBL6927914 0.87 TRPV3 (0.43) KCNH2PIK3C3LRRK2ITGB2ICAM1
SCHEMBL6925881 0.85 PIK3C3 (0.42) PIK3C3WNT1GSK3BDYRK1ALRRK2
SCHEMBL6924980 0.85 DRD2 (0.42) KCNH2PIK3C3DRD2HTR2AITGB2
SCHEMBL6921614 0.84 CDK1 (0.43) PIK3C3WNT1GSK3BDYRK1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514966-B2 Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine PFIZER INC. 2003-02-04 US disclosed
US-6355635-B1 IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY PFIZER INC. 2002-03-12 US disclosed
US-20010039277-A1 Compounds for the treatment of obesity ELLIOTT RICHARD L (US) 2001-11-08 US disclosed
WO-2000066578-A1 COMPOUNDS FOR THE TREATMENT OF OBESITY PFIZER PRODUCTS INC. (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039277-A1 Compounds for the treatment of obesity NPY1R, NPY4R, NPY2R KCNH2 3992/4885PIK3C3 4567/4885WNT1 3698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.